Project 2: Strategies for Reducing Nicotine Content in Cigarettes
NCT ID: NCT02139930
Last Updated: 2018-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1250 participants
INTERVENTIONAL
2014-09-30
2017-03-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes
NCT02301325
Novel Determinants and Measures of Smokeless Tobacco Use: Study 2
NCT01067599
Project 2 Cigarette and E-cigarette Nicotine Content and E-liquid Flavors
NCT03185546
Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes
NCT01681875
Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
NCT02000921
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal Nicotine Control Group
These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.
Normal Nicotine Control Group
Participants will smoke experimental cigarettes for a period of 20-weeks.
Immediate Nicotine Reduction Group
This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes. They will smoke these cigarettes for 20 weeks.
Immediate Nicotine Reduction Group
Participants will smoke experimental cigarettes for a period of 20-weeks.
Gradual Nicotine Reduction Group
This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.
Gradual Nicotine Reduction Group
Participants will smoke experimental cigarettes for a period of 20-weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Normal Nicotine Control Group
Participants will smoke experimental cigarettes for a period of 20-weeks.
Immediate Nicotine Reduction Group
Participants will smoke experimental cigarettes for a period of 20-weeks.
Gradual Nicotine Reduction Group
Participants will smoke experimental cigarettes for a period of 20-weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Daily smokers who smoke an average of at least five cigarettes per day for at least 1 year
3. Breath CO levels \> 8 ppm (if ≤ 8 ppm, then NicAlert Strip level must indicate regular smoking)
Exclusion Criteria
2. Currently seeking treatment for smoking cessation
3. Currently using nicotine replacement therapies or other pharmacotherapies as cessation aid (non-cessation intermittent use acceptable)
4. A quit attempt in the past 30 days resulting in greater than 3 days of abstinence
5. Using other tobacco products or e-cigarettes more than 9 days in the past 30 days
6. Significant unstable medical conditions (Any significant change in a serious medical condition occurring during the past 3 months including, cardiovascular disease, COPD, and cancer, as determined by the licensed medical professional at each site)
7. Unstable psychiatric conditions (Any significant change in psychiatric symptoms during the past 3 months as determined by the licensed medical professional at each site)
8. Schizophrenia and schizoaffective disorder
9. Psychiatric medication changes (e.g., new prescriptions, changes in dosages, or discontinuation of medications) in the past 3 months that was a result of negative changes in symptoms.
10. Positive toxicology screen for any of the following drugs: cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP
1. Marijuana will be tested for but will not be an exclusionary criterion.
2. Participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone will not be excluded.
3. Participants failing the toxicology screen will be allowed to re-screen once.
11. Blood alcohol level \> 0.01
a. Participants failing the blood alcohol screen will be allowed to re-screen once.
12. Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 drinks per day (female/male))
13. Pregnant, trying to become pregnant or breastfeeding
14. Predominant use of 'roll your own cigarettes'
15. CO reading \>80 ppm
16. Systolic BP greater than or equal to 160
a. Participants failing for blood pressure will be allowed to re-screen once.
17. Diastolic BP greater than or equal to 100
a. Participants failing for blood pressure will be allowed to re-screen once.
18. Systolic BP below 90 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for blood pressure will be allowed to re-screen once.
19. Diastolic BP below 50 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for blood pressure will be allowed to re-screen once.
20. Heart rate greater than or equal to 105 bpm
a. Participants failing for heart rate will be allowed to re-screen once.
21. Heart rate lower than 45 bpm and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
a. Participants failing for heart rate will be allowed to re-screen once.
22. Indicating any suicidal ideation in the past month, suicide attempts in the past 5 years (if within past 5 to 10 years, requires physician approval), or score of \>4 on the MINI suicide subscale
23. Household member enrolled in the study concurrently.
24. Inability to independently read and comprehend the consent form and other written study materials and measures because participants are required to complete parts of the protocol at home independently.
25. Participated in prior study that involved reduced nicotine content cigarettes.
26. Having participated in a research study during the past three months in a study that would impact baseline smoking or response to study products.
27. Currently taking the following anticonvulsant medications:
1. Phenytoin \[Brand Name: Dilantin\]
2. Carbamazepine \[Brand Name: Tegretol, Carbatrol, Equetro, Epitol\]
3. Oxcarbazepine \[Brand Name: Trileptal\]
4. Primidone \[Brand Name: Mysoline\]
5. Phenobarbital
28. Currently taking the following medication:
1. Bendamustine (Treanda)
2. Clopidogrel (Plavix)
3. Clozapine (Clozaril, FazaClo)
4. Erlotinib (Tarceva)
5. Flecainide (Tambocor)
6. Fluvoxamine (Luvox)
7. Irinotecan (Camptosar)
8. Olanzapine (Zyprexa)
9. Ropinirole (Requip)
10. Tacrine (Cognex)
11. Theophylline (Theo Dur, etc.)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Wake Forest University Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Donny, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Phoenix, Arizona, United States
University of California San Francisco
San Francisco, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
Johns Hopkins University
Baltimore, Maryland, United States
University of Minnesota Medical School Duluth
Duluth, Minnesota, United States
University of Minnesota
Minneapolis, Minnesota, United States
Duke University
Durham, North Carolina, United States
Oregon Research Institute
Eugene, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
MDAnderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hatsukami DK, Luo X, Jensen JA, al'Absi M, Allen SS, Carmella SG, Chen M, Cinciripini PM, Denlinger-Apte R, Drobes DJ, Koopmeiners JS, Lane T, Le CT, Leischow S, Luo K, McClernon FJ, Murphy SE, Paiano V, Robinson JD, Severson H, Sipe C, Strasser AA, Strayer LG, Tang MK, Vandrey R, Hecht SS, Benowitz NL, Donny EC. Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA. 2018 Sep 4;320(9):880-891. doi: 10.1001/jama.2018.11473.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U54 DA031659-P2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.